Translating Biomedical Research into Innovative Therapeutic Solutions

Vivekbiopharma Establishes Its Corporate Base in Kerala

Vivekbiopharma Pvt. Ltd. has officially shifted its Registered Office from Tamil Nadu to Kerala, marking an important milestone in the Company’s growth. The change was formally registered with the Registrar of Companies (RoC), Ernakulam, on 18 July 2026.

The Company's Corporate Identity Number (CIN):U21001KL2024PTC104808.

Registered Office is:

Vivekbiopharma Private Limited, Gitanjali,

TC No. 18/1113(5), TRA85D Tagore Road,

Thrikkannapuram, Aramada Thiruvananthapuram – 695032

Kerala, India

This transition aligns our corporate presence with our expanding R&D activities in Kerala, including our incubation at Dr. Moopen’s BioNEST, Wayanad. With two new intellectual-property assets emerging from our recent R&D programme, Vivekbiopharma is strengthening its position within Kerala’s biotechnology ecosystem and advancing its innovative therapeutic technologies toward preclinical validation, industry collaboration and commercialisation.

Our R&D strategy combines expertise in plasma proteins, albumin-based drug conjugation, fibrin biomaterials, drug delivery, inflammation biology and translational biomedical research. We aim to develop practical therapeutic technologies that can progress from laboratory proof of concept through preclinical validation and ultimately toward clinical translation and commercialisation.

Vivekbiopharma is currently incubated at Dr Moopen’s BioNEST in Wayanad, Kerala, where our research team conducts formulation development, in vitro evaluation, and proof-of-concept studies.

Our Mission

01

Unmet Clinical Need

02

Scientific Concept

Prototype

In Vitro Proof-of-Concept

03

04

05

Intellectual Property

06

Preclinical Validation

07

Clinical Translation

Our current programmes are progressing through proof-of-concept and preclinical development.

The generation of two IPR assets from our recent R&D programme represents an important milestone in the company's transition from an early-stage biotechnology venture toward an intellectual-property-driven therapeutic development company.

08

Commercialization

The Team

Lissy K. Krishnan

Managing Director, Vivekbiopharma Pvt. Ltd.

Dr. Lissy K. Krishnan is a distinguished biomedical scientist with over four decades of pioneering experience in biomaterials, tissue engineering, and regenerative medicine. As a former senior faculty member and head of the Biomedical Technology Wing at Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), she has led translational research that bridged material science and clinical practice. Her contributions span cardiovascular biomaterials, wound-healing matrices, and fibrin-based delivery systems for drugs and bioactives. Dr. Krishnan has mentored numerous scientists and clinicians, resulting in impactful collaborations and innovations with direct clinical applications.

At Vivekbiopharma, she provides strategic scientific leadership in developing hybrid PLGC-fibrin and bioactive composite platforms for cancer drug delivery and wound healing. Her work emphasizes scalable, safe, and regulatory-compliant technologies that integrate natural and synthetic systems. With over 100 publications, multiple patents, and recognized excellence in translational science, Dr. Krishnan continues to shape India’s biomaterials research landscape and guide next-generation biotherapeutic innovation.

Dr. Shruti Venkitachalam

Director, Vivekbiopharma Pvt. Ltd.

Dr. Shruti Venkitachalam is a clinician-scientist specializing in head and neck onco-reconstructive surgery, with extensive experience in cancer management and clinical translational research. She holds an MBBS from BLDEA’s Shri B.M. Patil Medical College, an MS and DNB in ENT from Kasturba Medical College, Manipal, and postdoctoral fellowship training in Head and Neck Onco-Reconstruction from Christian Medical College, Vellore.

Currently a Consultant at Apollo Cancer Centre, Chennai, Dr. Venkitachalam’s career integrates surgical precision with translational oncology. Her training as a UICC and FHNO Fellow has shaped her global perspective on cancer care and advanced reconstructive approaches. She has authored several peer-reviewed publications addressing complex surgical cases and novel therapeutic insights.

At Vivekbiopharma, she bridges clinical oncology with bioengineering innovation, ensuring the company’s cancer-targeted drug delivery technologies align with unmet medical needs. Her clinical insight strengthens product validation and patient-centric translational pathways, fostering a bridge between laboratory innovation and clinical relevance.

Dr. Tara Sudhadevi

Promoter & Shareholder, Vivekbiopharma Pvt. Ltd.

Dr. Tara Sudhadevi is a biomedical researcher with strong translational expertise in tissue injury, repair, and regeneration. A PhD graduate from the Thrombosis Research Unit, SCTIMST, her research integrates molecular biology, stem cell science, and biomaterials to advance therapies for neural and pulmonary injury.

Currently a DHR-NRI Faculty at Cochin University of Science and Technology, she leads research on the Lung-Brain Axis and hyperoxia-induced injury, employing organoid and precision-cut lung models. She previously served as Senior Research Associate and Postdoctoral Scientist at Case Western Reserve University, USA, where she explored oxidative stress-mediated lung and brain injury and regeneration using spatial transcriptomics and stem cell models.

Dr. Sudhadevi’s key publications in Biomedical Materials, Journal of Applied Physiology, and Journal of Neural Engineering underscore her innovation in fibrin hydrogel systems and regenerative therapies. At Vivekiopharma, she contributes to the design and evaluation of biomimetic matrices for tissue repair and localized drug delivery, strengthening the company’s R&D in regenerative and anti-inflammatory technologies.

Dr. Renu Ramesh

Promoter, Vivekiopharma Pvt. Ltd.

Dr. Renu Ramesh is a biomedical scientist specializing in stem cell differentiation, biomaterial-based tissue models, and regenerative therapeutics. She holds a PhD in Biological Sciences from SCTIMST, Trivandrum, an M.Sc. in Life Sciences from Pondicherry University, and a B.Sc. in Biochemistry from the University of Kerala.

Currently a Scientist-C at the Regional Cancer Centre, Trivandrum,
Dr. Ramesh has over 15 years of research experience spanning tissue engineering, vascular biology, and stem cell differentiation. Her studies have advanced understanding of human adipose-derived mesenchymal stem cell differentiation into cardiac and vascular lineages using fibrin-based matrices. She has received multiple research awards, including the Best Poster and Best Paper recognitions at national scientific meetings.

At Vivekbiopharma, Dr. Ramesh contributes to product development and testing of natural bioactive-embedded biomaterials for wound healing and cancer adjunct therapies. Her blend of cell biology expertise and biomaterial innovation drives the company’s translational pipeline toward safe and effective clinical products.

Dr. Aswathy I.S.

Full-time Scientist & Shareholder, Vivekbiopharma Pvt. Ltd.

Dr. Aswathy I.S. is a dynamic researcher in biomaterials and drug delivery, with expertise in plant-derived molecules and their therapeutic translation. Trained at University of Kerala, her work focuses on integrating bioactive natural compounds with nanomaterials for sustained drug delivery in cancer therapy and tissue repair.

At Vivekbiopharma, she leads experimental programs on fibrin-based drug delivery systems, establishing in vitro and in vivo models to evaluate release kinetics, biocompatibility, and therapeutic efficacy. Her goal is to develop novel, natural molecule-embedded biomaterials as adjuncts to conventional therapies.

Dr. Aswathy’s work strengthens Vivekbiopharma’s position in combining biotechnology, pharmacology, and material science for next-generation localized therapeutics. Her focus on translational validation and regulatory compliance ensures the scientific robustness of the company’s preclinical development program.

Transforming proven biological materials and medicines into smarter therapeutic platforms.

Our vision is to develop affordable, scientifically robust and clinically translatable biomedical technologies that address unmet healthcare needs.

We believe that innovation does not always require discovering a completely new drug. Significant clinical value can also be created by improving how existing medicines are formulated, delivered, localized and combined.

Our Innovation Pipeline

Vivekbiopharma is building a focused portfolio of proprietary technologies in cancer therapeutics and advanced drug delivery. Our current innovation pipeline includes two intellectual properties.

Collaboration & Partnerships

Vivekbiopharma welcomes collaborations with:

Pharmaceutical and biotechnology companies | Oncology centres | Academic institutions | Preclinical research organizations | Clinician-scientists | Investors and technology-development partners

We are particularly interested in partnerships supporting preclinical validation, regulatory development, manufacturing scale-up, clinical translation, licensing and commercialization of our proprietary technologies.

Our collaboration with INXH Research Pvt Ltd, a Private Limited company having its principal place of business at Thejas Kedakulam Elakamon PO Varkala Pin Code 695310, State Name: Kerala, CIN-U72100KL2025PTC094347, has resulted in the development of a device for ontrolling the delivery of precise volumes of of the fibri-drug depot to the canceer tissue.

Vivekbiopharma collaborates with INXH Research Pvt. Ltd., a Kerala-based technology company, to develop precision-controlled delivery systems for our injectable therapeutic platforms. This collaboration has resulted in a specialized device capable of accurately controlling the delivery of predetermined volumes of fibrin-drug formulations directly to cancer tissue. The device supports consistent administration, controlled flow and localized depot formation, which are essential for achieving reproducible therapeutic performance and minimizing systemic drug exposure.

This partnership is strategically important because Vivekbiopharma’s innovation pipeline extends beyond a single product. Our current and future technologies require injectable delivery across a broad volume range—from microvolume administration for localized cancer therapy to larger-volume delivery for tissue regeneration and wound-healing applications. By combining Vivekbiopharma’s expertise in biomaterials, protein-based drug carriers and therapeutic formulation with INXH Research’s engineering capabilities, we aim to develop adaptable, user-friendly delivery systems that support precise clinical administration and facilitate the translation of innovative therapies from laboratory research to patient care.

Biomedical Engineering

Prototype of a Handheld Injection System

Dr Moopen’s iNEST, Wayanad, an incubation centre supporting healthcare startups, provides excellent incubation services to Vivek Biopharma Pvt. Ltd.,for developing sustained local drug delivery systems. The engagement commenced on 8 September 2025 for a period of two years, with the option for mutual extension. Vivek Biopharma has access to co-working space, IP and regulatory consulting through iNEST’s partners at preferential rates, and limited financial support for external events, reflecting a comprehensive ecosystem for innovation and translation in healthcare. During the past year, the focused R&D with iNEST support has resulted in the development of two intellectual-property assets covering novel therapeutic and localised drug-delivery approaches for cancer treatment.

Summary of Incubation Services – Dr Moopen’s iNEST & Outcome

Dr. Santhoshkumar T.R., Scientist G and Head, Cancer Biology, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, and his research team. With expertise in evaluating therapeutic approaches for cancer, Dr. Santhoshkumar and his laboratory have provided valuable scientific guidance and experimental support for the in vitro studies that established proof-of-concept for both of Vivekbiopharma’s cancer therapeutic technologies. Their contribution has been instrumental in advancing these innovations toward further preclinical development.

Clinical & Translational Collaboration

Cancer Biology & In Vitro Research Collaboration

Vivekbiopharma is collaborating with a team of experienced oncologists from the Regional Cancer Centre (RCC), Thiruvananthapuram, led by a senior clinician-administrator. The team provides valuable clinical mentorship for the further development of our Two-Component
Fibrin-Based Depot for Sequential Localized Cancer Drug Delivery (IPR 2), helping align the technology with unmet clinical needs and practical oncology applications. The collaboration is expected to guide indication selection, preclinical development and future clinical translation. Following successful generation of the required in vivo preclinical safety and efficacy data and applicable CDSCO regulatory approvals, the collaboration is intended to progress toward clinical evaluation of the technology.

With a strong base in wound healing and skin regeneration platforms, we are developing an injectable “Biomimetic Extracellular Matrix for Skin Regeneration.” Fibrinogen, gelatin, and hyaluronic acid are the ECM components in the composite matrix that promote skin regeneration. The PoC experiments are in progress. In this context, Vivekbiopharma collaborates with Medvital Ventures Private Limited for the commercialisation of innovative wound-healing platforms. The collaboration brings together complementary expertise to advance promising wound-care technologies from product development toward validation, market readiness, and commercialization, with a focus on clinically relevant and accessible solutions.

Preclinical (in vivo) Research Partnership

Wound Healing Innovation

Palamur Biosciences Pvt. Ltd. (PBS), Hyderabad, a preclinical Contract Research Organization (CRO), is our proposed partner for the in vivo preclinical evaluation of Vivekbiopharma’s products and technologies. The collaboration is intended to support systematic assessment of safety, efficacy and other preclinical parameters required for advancing our innovations toward regulatory evaluation and subsequent clinical translation.

Innovation

Transforming proven biological materials and medicines into smarter therapeutic platforms.

CONTACT

admin@vivekbiopharma.com

+91 9447046727

© 2026. All rights reserved.